Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

G2GBIO

Obesity Weekly News

Obesity Today—March 17, 2026

This week’s Obesity update highlights regulatory approvals, emerging generic…

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration

Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Women’s Health Today—March 18, 2026
Neuroscience Today—March 18, 2026
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Obesity Today—March 17, 2026

Tags

APDS BESREMi breast cancer research Cardiovascular Research computational biology Denosumab-qbde Dentomi Edge Artificial Intelligence Epetraborole Fentanyl vaccine FSGS Generic obesity drugs Genetic therapies Genitourinary Cancers Global Biosimilar Week healthcare strategy Henlius Biotech INOVIO Pharmaceuticals interstitial lung disease LAMA2-related congenital muscular dystrophy LDL liver safety Longevity Market marketing strategy medical AI neuroblastoma NSLC Oncology News online patient communities pharmaceutical commercialization Pompe disease Portal Diabetes ProteoCharts psoriatic arthritis reSET RSV Vaccine SEQSTER sweetener Targeted Therapy Tivoxavir Marboxil vapendavir Weight Loss Science Yescarta Ziftomenib Zovegalisib

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Women’s Health Today—March 18, 2026
Neuroscience Today—March 18, 2026
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Obesity Today—March 17, 2026

TAGS

APDS BESREMi breast cancer research Cardiovascular Research computational biology Denosumab-qbde Dentomi Edge Artificial Intelligence Epetraborole Fentanyl vaccine FSGS Generic obesity drugs Genetic therapies Genitourinary Cancers Global Biosimilar Week healthcare strategy Henlius Biotech INOVIO Pharmaceuticals interstitial lung disease LAMA2-related congenital muscular dystrophy LDL liver safety Longevity Market marketing strategy medical AI neuroblastoma NSLC Oncology News online patient communities pharmaceutical commercialization Pompe disease Portal Diabetes ProteoCharts psoriatic arthritis reSET RSV Vaccine SEQSTER sweetener Targeted Therapy Tivoxavir Marboxil vapendavir Weight Loss Science Yescarta Ziftomenib Zovegalisib

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy